Bio-Rad Laboratories, Inc. (BIO) EPS Estimated At $1.35

July 11, 2018 - By Louis Casey

Bio-Rad Laboratories, Inc. (NYSE:BIO) LogoInvestors sentiment decreased to 1.03 in Q1 2018. Its down 0.10, from 1.13 in 2017Q4. It dropped, as 18 investors sold Bio-Rad Laboratories, Inc. shares while 101 reduced holdings. 42 funds opened positions while 81 raised stakes. 18.53 million shares or 0.19% less from 18.57 million shares in 2017Q4 were reported.
Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 1,165 shares in its portfolio. 21,460 were accumulated by Amp Ltd. Twin Tree Ltd Partnership stated it has 0.01% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). Westfield Lp holds 248,444 shares or 0.48% of its portfolio. Vanguard Group reported 1.75M shares. Manufacturers Life Insur Co The owns 224,505 shares. Art Advsrs Limited Co stated it has 3,800 shares. Balyasny Asset Ltd Co stated it has 0.04% in Bio-Rad Laboratories, Inc. (NYSE:BIO). 88,336 are held by Principal Financial Gru. Natixis holds 0.02% or 11,995 shares. Moreover, Liberty Mutual Group Inc Asset Mngmt has 0.03% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO). Jefferies Grp Inc Limited Liability Corporation holds 0% or 1,014 shares in its portfolio. Hawaii-based C M Bidwell Ltd has invested 0.81% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Paloma Partners Co holds 0.01% in Bio-Rad Laboratories, Inc. (NYSE:BIO) or 2,722 shares. Point72 Asia (Hong Kong) Ltd holds 0.02% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 118 shares.

Since June 13, 2018, it had 0 buys, and 1 insider sale for $106,197 activity.

Analysts expect Bio-Rad Laboratories, Inc. (NYSE:BIO) to report $1.35 EPS on August, 2.They anticipate $0.77 EPS change or 132.76 % from last quarter’s $0.58 EPS. BIO’s profit would be $39.95M giving it 55.46 P/E if the $1.35 EPS is correct. After having $1.17 EPS previously, Bio-Rad Laboratories, Inc.’s analysts see 15.38 % EPS growth. The stock decreased 1.15% or $3.48 during the last trading session, reaching $299.47. About 105,837 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 30.04% since July 12, 2017 and is uptrending. It has outperformed by 17.47% the S&P500.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Ratings Coverage

Among 3 analysts covering Bio-Rad Laboratories (NYSE:BIO), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Bio-Rad Laboratories had 4 analyst reports since February 16, 2018 according to SRatingsIntel. The company was downgraded on Friday, February 16 by C.L. King. CL King downgraded Bio-Rad Laboratories, Inc. (NYSE:BIO) on Friday, February 16 to “Neutral” rating. On Wednesday, February 28 the stock rating was maintained by Wells Fargo with “Outperform”. Wells Fargo maintained Bio-Rad Laboratories, Inc. (NYSE:BIO) on Tuesday, March 20 with “Buy” rating.

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company has market cap of $8.86 billion. The firm operates through two divisions, Life Science and Clinical Diagnostics. It has a 11.75 P/E ratio. The Life Science segment develops, makes, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

More recent Bio-Rad Laboratories, Inc. (NYSE:BIO) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares” on July 11, 2018. Also Streetinsider.com published the news titled: “Bio-Rad Labs (BIO) PT Raised to $350 at Deutsche Bank as Markets Remain Healthy” on June 21, 2018. Gurufocus.com‘s news article titled: “John Rogers’ Ariel Investments June Commentary” with publication date: July 09, 2018 was also an interesting one.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>